Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1429-1435

  Hamilton, Stephanie M ^a   Bayer, Clifford R ^a   Stevens, Dennis L ^a,b   Bryant, Amy E ^a,b  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

myonecrosis; NSAIDs; Streptococcus pyogenes

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ANTIBIOTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; CLINDAMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; KETOROLAC; KETOROLAC TROMETAMOL; PENICILLIN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GROUP A STREPTOCOCCAL INFECTION; MORTALITY; MOUSE; MUSCLE NECROSIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; SURVIVAL; TOXICITY TESTING;

MYONECROSIS; NSAIDS; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; MICE; MUSCULAR DISEASES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84898883202     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit594     Document Type: Article

References (29)

1. Bisno AL, Stevens DL. Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone, 2005:2362-79
2. Stevens DL. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977-80
3. Barnham MR, Weightman NC, Anderson AW, et al. Streptococcal toxic shock syndrome: A description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect 2002; 8:174-81
4. Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999; 103:783-90
5. Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001; 107:1108-15
6. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003; 82:225-35
7. Bondesen BA, Mills ST, Kegley KM, et al. The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 2004; 287:C475-83
8. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8:349-61
9. Stevens DL, Bryant-Gibbons AE, Bergstrom R, et al. The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-8
10. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-Tissue infections. Clin Infect Dis 2005; 41:1373-406
11. Stevens DL, Yan S, Bryant AE. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J Infect Dis 1993; 167:1401-5
12. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med 1991; 324:1716-25
13. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes Infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14:201-9
14. Souyri C, Olivier P, Grolleau S, et al. Severe necrotizing soft-Tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol 2008; 33:249-55
15. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-Acquired Clostridium difficile-Associated disease. JAMA 2005; 294:2989-95
16. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:1481-92
17. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes. J Infect Dis 1994; 170:609-14
18. Stevens DL, Tanner MH, Winship J, et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: Severe group A streptococcal infections associated with a toxic shock-like syndrome. N Eng J Med 1989; 321:1-7
19. Hamilton SM, Bayer CR, Stevens DL, et al. Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J Infect Dis 2008; 198:1692-8
20. Weng TC, Chen CC, Toh HS, et al. Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect 2011; 44:418-23
21. Stables MJ, Newson J, Ayoub SS, et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and-resistant bacteria. Blood 2010; 116:2950-9
22. Sadikot RT, Zeng H, Azim AC, et al. Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol 2007; 37:1001-9
23. Goldmann O, Hertzen E, Hecht A, et al. Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes. J Immunol 2010; 185:2372-81
24. Wallace JL, Bak A, McKnight W, et al. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Gastroenterology 1998; 115:101-9
25. Langenbach R, Loftin C, Lee C, et al. Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions. Biochem Pharmacol 1999; 58:1237-46
26. Aziz RK, Kansal R, Abdeltawab NF, et al. Susceptibility to severe Streptococcal sepsis: Use of a large set of isogenic mouse lines to study genetic and environmental factors. Genes Immun 2007; 8:404-15
27. Abdeltawab NF, Aziz RK, Kansal R, et al. An unbiased systems genetics approach to mapping genetic loci modulating susceptibility to severe streptococcal sepsis. PLoS Pathog 2008; 4:e1000042
28. Butler NS, Monick MM, Yarovinsky TO, et al. Altered IL-4 mRNA stability correlates with Th1 and Th2 bias and susceptibility to hypersensitivity pneumonitis in two inbred strains of mice. J Immunol 2002; 169:3700-9
29. Planaguma A, Claria J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving nonparenchymal cell apoptosis and PPARgamma activation. FASEB J 2005; 19:1120-2.